SWOG clinical trial number
CTSU/C80802

Phase III Randomized Study of Sorafenib plus Doxorubicin Versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma (HCC)

Closed
Phase
Abbreviated Title
Ph III HCC sorafenib +/- doxorubicin
Activated
06/01/2011
Closed
05/21/2015
Participants
CTSU

Research committees

Gastrointestinal Cancer

Treatment

Doxorubicin BAY 43-9006

Publication Information Expand/Collapse

2024

CALGB 80802 (Alliance): Impact of Sorafenib with and without Doxorubicin on Hepatitis C infection in Patients with advanced hepatocellular carcinoma

G Abou-Alfa;S Geyer;A Nixon;F Innocenti;Q Shi;S Jacobson;I El Dika;A Yaqubie;J Lopez;B Hwang;A El-Khoueiry;Y Tang;Y Wen;L Schwartz;M Bertagnolli;J Meyerhardt;E O'Reilly;A Venook Cancer Res Commun Feb 16. doi: 10.1158/2767-9764.CRC-22-0516. Online ahead of print

PMid: PMID38363156

2019

Assessment of Treatment With Sorafenib Plus Doxorubicin vs Sorafenib Alone in Patients With Advanced Hepatocellular Carcinoma: Phase 3 CALGB 80802 Randomized Clinical Trial

G Abou-Alfa;Q Shi;J Knox;A Kaubisch;D Niedzwiecki;J Posey;B Tan;P Kavan;R Goel;P Lammers;T Bekaii-Saab;VC Tam;L Rajdev;R Kelley;A El-Khoueiry;I El Dika;T Zemla;R Potaracke;J Balletti;L Schwartz;RM Goldberg;M Bertagnolli;J Meyerhardt;E O'Reilly;A Venook JAMA Oncology Sep 5;5(11):1582-1588; Sep 5;. doi: 10.1001/jamaoncol.2019.2792. [Epub ahead of print]

PMid: PMID31486832 | PMC number: PMC6735405

2018

Platelet count at baseline (Plt) and outcomes in patients (pts) with advanced hepatocellular carcinoma (HCC) treated with sorafenib (S) in CALGB80802 (Alliance) (C8)

G Abou-Alfa;Q Shi;J Knox;A Kaubisch;J Posey;B Tan;P Kavan;R Goel;P Lammers;T Bekaii-Saab;V Tam;L Rajdev;RK Kelley;A Siegel;T Zemla;I El Dika;A Venook;M Bertagnolli;J Meyerhardt;EM O'Reilly J Clin Oncol 36, 2018 (suppl; abstr e16107);ASCO Annual Meeting (June 1- 5, 2018, Chicago, IL), publication only

2016

Phase III randomized study of sorafenib plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC)- CALGB 80802

G Abou-Alfa;D Niedzwiecki;J Knox;A Kaubisch;A Siegel;B Tan;T Alcindor;T Bekaii-Saab;M Bertagnolli;A Venook Journal of Clinical Oncology 34:(suppl 4S; abstr 192); poster GI Cancers Symposium (1/21/16 - 1/23/2016, San Francisco, CA)

Phase III randomized study of sorafenib plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC): CALGB 80802 (Alliance)

G Abou-Alfa;D Niedzwieski;J Knox;A Kaubisch;J Posey;B Tan;P Kavan;K Goel;P Lammers;T Bekaii-Saab;V Tam;L Rajdev;R Kelley;A Siegel;J Balletti;J Harding;L Schwartz;R Goldberg;M Bertagnolli;A Venook Journal of Clinical Oncology 34, 2016 (suppl; abstr 4003); American Society of Clinical Oncology Annual Meeting (June 3-7, 2016, Chicago, IL), oral presentation

Other Clinical Trials